When should teicoplanin, tigecycline, polymyxin B, and colistin be used, and what are the recommended dosing regimens and treatment durations for each?

Polymyxins (Colistin/Polymyxin B) vs Tigecycline: When to Use Each

For carbapenem-resistant Gram-negative infections, polymyxins (colistin or polymyxin B) are the preferred first-line agents over tigecycline, with polymyxin B potentially offering superior safety. Tigecycline should be avoided for hospital-acquired/ventilator-associated pneumonia and used cautiously for other indications due to increased mortality risk. Teicoplanin is reserved exclusively for Gram-positive infections and has no role in carbapenem-resistant Gram-negative coverage.

Agent Selection by Pathogen

Carbapenem-Resistant Acinetobacter baumannii (CRAB)

Polymyxins are strongly recommended as first-line therapy [1, 2:

• Intravenous colistin or polymyxin B (strong recommendation) 1
• Add adjunctive inhaled colistin (weak recommendation) 1
• Avoid tigecycline - strong recommendation against use for HAP/VAP caused by Acinetobacter 1

The evidence is clear: tigecycline demonstrates inferior outcomes compared to polymyxins for CRAB pneumonia 3. Multiple retrospective studies show higher mortality and lower clinical response with tigecycline monotherapy 3.

Carbapenem-Resistant Enterobacterales (CRE)

Prioritize newer beta-lactam/beta-lactamase inhibitors when available [2, 2:

• First-line: Ceftazidime/avibactam, meropenem/vaborbactam, or imipenem/relebactam
• Polymyxin-based combinations when above agents unavailable [2, 2:
  • Colistin + tigecycline (weak recommendation, low evidence) [2, 2
  • Colistin + meropenem by extended infusion (weak recommendation) [2, 2

For complicated intra-abdominal infections: Tigecycline monotherapy is acceptable (100 mg loading, then 50 mg q12h) [2, 2, but polymyxin combinations preferred for severe/unstable patients [2, 2.

Carbapenem-Resistant Pseudomonas aeruginosa (CRPA)

Colistin-based treatment recommended (weak recommendation, low evidence) [2, 2:

• Combination therapy controversial but suggested for severe infections [2, 2
• Consider ceftolozane/tazobactam or ceftazidime/avibactam if susceptible [2, 2

Dosing Regimens

Colistin (Colistin Methanesulfonate - CMS)

Loading dose is mandatory [2, [4, [4, 2:

• Loading: 9 million IU (5 mg CBA/kg) [2, [4, 4
• Maintenance: 4.5 million IU q12h (adjust by formula: 2.5 mg CBA × [1.5 × CrCl + 30] q12h) [2, [2, 2
• For CrCl >50 mL/min: 4.5 million IU q12h [4, 4
• Continuous renal replacement therapy: at least 9 million IU/day [4, 4

Critical conversion: 1 million IU = 80 mg CMS = 33 mg colistin base activity (CBA) [2, 5

Polymyxin B

Polymyxin B may have superior safety profile (lower nephrotoxicity than colistin) [4, 4:

• Loading: 2-2.5 mg/kg [4, 4
• Maintenance: 1.5-3 mg/kg/day divided q12h [4, 4
• No dose adjustment needed for renal replacement therapy [4, 4
• Conversion: 1 mg polymyxin B sulfate = 10,000 IU 5

Tigecycline

FDA-approved indications only: complicated skin/soft tissue and intra-abdominal infections [6, [6, 6:

• Loading: 100 mg IV [6, 6
• Maintenance: 50 mg IV q12h [6, 6
• Duration: 5-14 days for approved indications [6, 6
• Black box warning: increased all-cause mortality (0.6% absolute risk increase) [6, 6
• Contraindicated: HAP/VAP (greater mortality and decreased efficacy) [6, 6

Teicoplanin

Gram-positive coverage only - no role in carbapenem-resistant Gram-negatives 7:

• Loading: 6 mg/kg q12h for 3 doses (or 10-12 mg/kg q12h for 5 doses for severe infections) 8
• Maintenance: 6 mg/kg q24h 7
• Target trough: 15-30 mg/L for common MRSA infections 8

Treatment Duration by Infection Site

Standardized durations [1, 2:

• Pneumonia (HAP/VAP): 7 days (strong recommendation) 1
• Bloodstream infections: 7-14 days [2, 2
• Complicated UTI: 5-7 days [2, 2
• Complicated intra-abdominal: 5-7 days [2, 2

Critical Safety Monitoring

Nephrotoxicity Risk Hierarchy

Highest to lowest: Colistin > Polymyxin B > Tigecycline [4, [4, 3

For polymyxins [2, [2, 9:

• Monitor renal function closely (strong recommendation) [2, 2
• AKI risk increases with: Cmin ≥2.3 µg/mL, AUC ≥82 mg·h/L 9
• Avoid combining with vancomycin or piperacillin-tazobactam (increases AKI risk 9-21 fold) 9
• Age >73 years increases AKI risk 3.6-fold 9

For tigecycline:

• Hepatotoxicity monitoring required 6
• Avoid in severe hepatic impairment (reduce to 25 mg q12h if Child-Pugh C) [6, 6

Combination Therapy Strategy

Polymyxin combination therapy preferred over monotherapy (strong recommendation, moderate evidence) 5:

Best evidence for combinations [2, [2, [2, 10:

1. Colistin + tigecycline: Demonstrated synergy for CRE bloodstream infections and CRAB [2, [11, 10
2. Colistin + meropenem (extended infusion): For CRE when meropenem MIC ≤8 mg/L [2, [2, 5
3. Colistin + rifampicin: NOT recommended for Acinetobacter (weak recommendation against) 1

Network meta-analysis findings 2: Colistin + carbapenem showed highest survival probability (SUCRA 83.6%) for CRAB bacteremia, followed by colistin + tigecycline (SUCRA 70.1%).

Common Pitfalls to Avoid

1. Using tigecycline for pneumonia: Strongly contraindicated for HAP/VAP [1, [6, 6
2. Omitting loading dose: Subtherapeutic levels for 2-3 days without loading [4, 4
3. Dose unit confusion: Always verify CMS vs CBA vs IU conversions [2, 5
4. Ignoring MIC: Adjust therapy based on susceptibility; consider adjunctive inhaled colistin for MIC ≥2 mg/L 12
5. Nephrotoxic drug combinations: Avoid vancomycin or piperacillin-tazobactam with polymyxins 9
6. Using teicoplanin for Gram-negatives: Zero activity against carbapenem-resistant Gram-negatives 7